| Autor: |
Mulet-Margalef N; Institut Català d'Oncologia, 08916 Badalona, Spain., Linares J; Institut Català d'Oncologia, 08916 Badalona, Spain.; Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain., Badia-Ramentol J; Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain., Jimeno M; Hospital Germans Trias i Pujol, 08916 Badalona, Spain., Sanz Monte C; Hospital Germans Trias i Pujol, 08916 Badalona, Spain., Manzano Mozo JL; Institut Català d'Oncologia, 08916 Badalona, Spain., Calon A; Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain. |
| Abstrakt: |
About 5 to 15% of all colorectal cancers harbor mismatch repair deficient/microsatellite instability-high status (dMMR/MSI-H) that associates with high tumor mutation burden and increased immunogenicity. As a result, and in contrast to other colorectal cancer phenotypes, a significant subset of dMMR/MSI-H cancer patients strongly benefit from immunotherapy. Yet, a large proportion of these tumors remain unresponsive to any immuno-modulating treatment. For this reason, current efforts are focused on the characterization of resistance mechanisms and the identification of predictive biomarkers to guide therapeutic decision-making. Here, we provide an overview on the new advances related to the diagnosis and definition of dMMR/MSI-H status and focus on the distinct clinical, functional, and molecular cues that associate with dMMR/MSI-H colorectal cancer. We review the development of novel predictive factors of response or resistance to immunotherapy and their potential application in the clinical setting. Finally, we discuss current and emerging strategies applied to the treatment of localized and metastatic dMMR/MSI-H colorectal tumors in the neoadjuvant and adjuvant setting. |
